AREC.L

Arecor Therapeutics plc [AREC.L] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AREC.L Stock Summary

Earnings have grown 107.51% per last year.

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

AREC.L

Top 10 Correlated Stocks

AREC.L

In the News

AREC.L Financial details

Company Rating

Market Cap

41.35M

Income

-14.13M

Revenue

5.07M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

22 Apr 2024

P/E

-5.31

Forward P/E

PEG

-0.73

P/S

21.67

P/B

2.82

P/C

P/FCF

-4.68

Quick Ratio

4.37

Current Ratio

4.69

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.47

EPS next Y

EPS next Q

EPS this Y

18.52%

EPS next Y

EPS next 5Y

EPS last 5Y

29.46%

Revenue last 5Y

26.3%

Revenue Q/Q

100%

EPS Q/Q

102.98%

SMA20

-18.86%

SMA50

-30.06%

SMA100

-50.33%

Inst Own

Inst Trans

ROA

-43%

ROE

-51%

ROC

-0.59%

Gross Margin

100%

Oper. Margin

-442%

Profit Margin

-385%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

130.0-299.0

52W High

-87.29%

52W Low

-70.77%

RSI

4.7

Rel Volume

Avg Volume

9.99K

Volume

Perf Week

Perf Month

-23.23%

Perf Quarter

-49.33%

Perf Half Y

-50.65%

Beta

-0.215

Volatility

0%, 4.64%

Prev Close

Price

Change

-3.31%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 9.99K
Market Capitalization 41.35M
Employee 51
CEO Dr. Sarah Jennifer Howell Ph.D.
Headquarters Little Chesterford,GB
IPO Date 2021-06-03
Website https://www.arecor.com

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.